Straight Talk from FDA: Wyeth R&D Head Reacts to Climate Change for NDA/BLA Reviews

Wyeth has had some tough times with FDA on its current crop of NDAs.Those experiences sent a team of senior execs down to FDA to find out what is up at the agency. What the execs heard was a call to action. The meeting "caused us at Wyeth to realize that we have to find a different way to operate." The current series of delays and rejections for important new drug applications is not a temporary situation for companies to ride out, but rather a sign of new regulatory

September was a critical month for the future of Wyeth.

The big news came at the end of the month, when Wyeth announced September 27 that Bernard Poussot would succeed...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet